BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) represents European small and medium-sized biotech companies involved in developing innovative products to tackle antimicrobial resistance, including preventative and curating therapies, and diagnostic tests.
BEAM gives its members a unique voice to propose and support policies and incentives in antimicrobial research and development in Europe.
BEAM recommends bold incentives that warrant action by policymakers to stimulate much needed innovation.
Company Details
- Employees
- 10
- Address
- 29 Avenue Tony Garnier, Lyon,auvergne-Rhône-Alpes 69007,france
- co****@****ance.eu
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- beam-alliance.eu
- Keywords
- Berlin.
- HQ
- Lyon, Auvergne-Rhône-Alpes
- Competitors
- CARB-X, BioVersys AG, Global Antibiotic R&D Partnership (GARDP), bamconn GmbH, AMR Action Fund, ESCMID - European Society of Clinical Microbiology and Infectious Diseases, AUROBAC THERAPEUTICS, The International Centre for Antimicrobial Resistance Solutions (ICARS), Nostics, AMR Industry Alliance.
Beam Alliance Questions
Beam Alliance's website is beam-alliance.eu
Beam Alliance's LinkedIn profile is https://fr.linkedin.com/company/beam-alliance
Beam Alliance has
10 employees.
View email and phone details for 10
employees at Beam Alliance.
Beam Alliance's industry is
Biotechnology Research
Beam Alliance's top competitors are
Carb-X,
Bioversys Ag,
Global Antibiotic R&d Partnership (Gardp),
Bamconn Gmbh,
Amr Action Fund,
Escmid - European Society Of Clinical Microbiology And Infectious Diseases,
Aurobac Therapeutics,
The International Centre For Antimicrobial Resistance Solutions (Icars),
Nostics,
Amr Industry Alliance.
Beam Alliance's support email address is contact@beam-alliance.eu
Beam Alliance's categories are Biotechnology Research
